Using Brain Stimulation to Reduce Fatigue and Cognitive Problems in Adults with Long COVID
Led by Amsterdam UMC, location VUmc · Updated on 2025-12-19
66
Participants Needed
1
Research Sites
25 weeks
Total Duration
AI-Summary
What This Trial Is About
This research focuses on adults experiencing long COVID, also called Post-COVID Condition or Post-Acute Sequelae of COVID-19 PASC, who suffer from severe fatigue and trouble concentrating. The study aims to evaluate whether repetitive transcranial magnetic stimulation rTMS, a non-invasive brain stimulation technique, can reduce fatigue and improve cognitive function. Previous research suggests that brain blood flow and inflammation changes may underlie these symptoms, and rTMS has shown promise in related conditions.
Participants will be randomly assigned to receive either active rTMS or a sham placebo version over a period of six weeks, with four sessions each week, totaling 24 sessions. Active rTMS involves delivering magnetic pulses to a specific brain area identified by MRI scans during a planning task, while sham treatment mimics the procedure without effective stimulation. Treatment targets the left dorsolateral prefrontal cortex, and the environment is adjusted to reduce sensory stress for participants.
Participants will undergo assessments before treatment, shortly after, and during follow-ups at three and six months. These include fatigue measurements, cognitive tests, brain imaging MRI, blood biomarker analysis, physical performance tests, and surveys on mood, sleep, and quality of life. Activity levels are tracked with a watch, and safety monitoring occurs throughout. The study lasts several months to observe effects and gather detailed information on brain and body changes related to treatment.
CONDITIONS
Brief Title
Brain Stimulation in Long COVID
Research Team
C
Céline N Dietz, MSc, MA
S
Sander C.J. Verfaillie, Dr.
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match. Sign up to get personalized trial recommendations delivered to your inbox.
ZonMw: The Netherlands Organisation for Health Research and Development
Collaborating Sponsor
Who Can Participate
Age: 18Years +
All Genders
Eligibility Criteria
You may qualify if you...
Meet the World Health Organization (WHO) definition of long COVID
Aged 18 years or older
Severe fatigue, defined as a score of 35 or higher on the Checklist Individual Strength (CIS) fatigue subscale
Significant cognitive complaints, defined as a score of 18 or higher on the CIS concentration subscale
Commitment to actively undergo rTMS
Ability to attend the study site regularly for treatment sessions
Capacity to provide written informed consent
You will not qualify if you...
Prior rTMS treatment or current intensive/experimental treatment for long COVID
History of epilepsy or first-degree family history of epilepsy
Recent start or dosage change of psychotropic medication less than six weeks ago (including antidepressants and antipsychotics) or less than two weeks for benzodiazepines
Other active pharmacological treatments for post-COVID symptoms
Contraindications to MRI (e.g., non-removable metal implants, severe claustrophobia)
Presence of cochlear implant
Neurological disorders such as multiple sclerosis or neurodegenerative diseases
Pregnancy
Known brain lesions or ischemic scars affecting seizure threshold
Severe uncontrolled migraines
Severe cardiovascular disease
Raised intracranial pressure
High alcohol consumption (males: over 21 units/week; females: over 14 units/week) or use of epileptogenic drugs
Severe sleep deprivation at time of treatment
Your Study Journey
Screening
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Implementation
Duration - 6 weeks
Participants receive brain stimulation treatment using repetitive transcranial magnetic stimulation (rTMS) or sham stimulation. Treatment is delivered four times per week for six consecutive weeks, totaling up to 24 sessions with a minimum effective dose of 16 sessions to accommodate participant burden.
4 visits per week for 6 weeks
Follow-up
Duration - 4 months
Participants return for outcome assessments to evaluate fatigue, cognitive function, and other health measures at 3 and 6 months after treatment to assess long-term effects.
2 visits (at 3 and 6 months post-treatment)
How is the study designed?
Study Type
INTERVENTIONAL
Masking
TRIPLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Similar Trials
Study of Anktiva Interleukin-15 Superagonist Nogapendekin Alfa Inbakicept Treatment for Adults With Long COVID
Safety Evaluation of Nogapendekin Alfa Inbakicept Anktiva for Adults with Long COVID
Pilot Study of Acupuncture and Chinese Herbal Medicine for Adults with Long COVID
Study of HIV Antiviral Drugs Truvada and Selzentry to Reduce Symptoms in Adults with Long Covid
Using Brain Stimulation to Reduce Fatigue and Cognitive Problems in Adults with Long COVID
Open Trial of DAOIB to Treat Cognitive Impairment Caused by COVID-19
Study of Voice Biomarkers in Long COVID Using the Long COVID Companion App to Track Symptom Evolution and Health
Study of Breathing Problems in Adults With Post COVID-19 Condition
RECLAIM Study Evaluating Hi-OxSR and Hi-Ox Devices for Treating Post COVID Cognitive Dysfunction with Adaptive Integrative Medicine
Evaluating Transcranial Direct Current Stimulation for Persistent COVID-19 Symptoms
Including Headaches and Chronic Pain
Have more questions? Get in touch with our team for quick support
Published Research Related To This Trial
Greater fatigue is more strongly associated with reduced reward sensitivity in the long-term phase of coronavirus disease (COVID-19) than in the early phase.
Judith M Scholing, Britt I H M Lambregts, Ruben van den Bosch...
Safety and recommendations for TMS use in healthy subjects and patient populations, with updates on training, ethical and regulatory issues: Expert Guidelines.
Is the efficacy of repetitive transcranial magnetic stimulation influenced by baseline severity of fatigue symptom in patients with myalgic encephalomyelitis.
Neuropsychological functioning after COVID-19: Minor differences between individuals with and without persistent complaints after SARS-CoV-2 infection.
Anouk Verveen, Sander C J Verfaillie, Denise Visser...